Share on LinkedInShare on LinkedIn

ARTICLE · 09 OCTOBER 2018

The USMCA: What Does It Mean For Patents And The Pharmaceutical Industry?

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

In a joint statement on September 30, 2018, the United States and Canadian Governments announced that they reached an agreement, alongside Mexico, on a new, modernized trade agreement for the 21st century.

CanadaIntellectual Property

In a joint statement on September 30, 2018, the United States and Canadian Governments announced that they reached an agreement, alongside Mexico, on a new, modernized trade agreement for the 21st century.1 The pending trilateral deal, called the United States-Mexico-Canada Agreement (USMCA), is intended to replace the North American Free Trade Agreement (NAFTA) currently in force.

The text of the USMCA was published on the Office of the United States Trade Representative website shortly after the formal agreement was announced.2 The deal includes updated provisions governing the protection and enforcement of intellectual property (IP) rights which, if ratified, will modify the legal and regulatory landscape for the pharmaceutical industry in Canada, notably in the field of biologics. The following is a summary of what is new and what will likely remain the same after the USMCA comes into force.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from